The drugs have names that sound like small planets: semaglutide, liraglutide, lixisenatide. Collectively, they belong to a class of glucagon-like peptide 1 (GLP-1) analogs that has reshaped the treatment of obesity and diabetes so thoroughly that the word “blockbuster” barely covers it. And yet, for all the billions of dollars spent, for all the prescriptions written, a fundamental question has lingered like a low hum beneath the clinical noise: where, precisely, does GLP-1 live inside the brain, and does it set up house differently in females and males? A new study published in Brain Medicine answers both questions with startling clarity.
This article was originally published on MedicalXpress.com
